Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients

Therapeutic management of the CDI, including the starting date of the treatment, CDI treatment first line and associated treatment

For patients treated with fidaxomicin

Time frame: Day 1

Number and timing of recurrences in patients treated with fidaxomicin over a 3-month follow-up period

Time frame: End of the follow-up (3 months)

Adverse events and serious adverse events occurring on fidaxomicin

Time frame: End of the follow-up (3 months)

Characteristics of patients diagnosed with CDI, including demographic data and treatment by antibiotherapy

For all patients diagnosed with CDI regardless of treatment

Time frame: Day 1

Characteristics of the CDI, including date of CDI diagnosis, Department requesting the diagnosis of CDI, methods used, severity of CDI and origin of the case

For all patients diagnosed with CDI regardless of treatment

Time frame: Day 1

Treatment of the CDI including treatment selected and dosage

For all patients diagnosed with CDI regardless of treatment